
Claims

1. A use of a compound represented by a following formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof, in the manufacture of a medicament for eradicating Helicobacter pylori:

[Formula 1]




wherein the medicament increases an intragastric pH to 5 or more within three hours after administration thereof, and

wherein a percentage of time at which an intragastric pH is maintained at 5.0 or more for a period of up to 24 hours after administration thereof is at least 60% in case of the medicament.

2. The use according to claim 1, wherein the compound represented by the formula 1 is a compound represented by a following formula 2:

[Formula 2]



3. The use according to claim 1, wherein a content of the compound represented by the formula 1 or pharmaceutically acceptable salts thereof is 10 mg to 500 mg, a content of amoxicillin or pharmaceutically acceptable salts thereof is 100 mg to 4 g, and a content of clarithromycin or pharmaceutically acceptable salts thereof is 50 mg to 3 g.

4. The use according to claim 1, wherein a percentage of time at which an intragastric pH is maintained at 6.0 or more for a period of up to 24 hours after administration thereof is at least 80% in case of the compound represented by the formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof.

5. The use according to claim 1, wherein the compound represented by the formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof increase an intragastric pH to 6.0 or more within two hours after

administration thereof.

6. The use according to claim 1, wherein the compound represented by the formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof eradicate *Helicobacter pylori* resistant to antibiotics.

7. The use according to claim 6, wherein the *Helicobacter pylori* resistant to antibiotics is resistant to amoxicillin or clarithromycin.

8. The use according to claim 1, wherein the compound represented by the formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof are administered into subjects infected with *Helicobacter pylori*.

9. The use according to claim 8, wherein the *Helicobacter pylori* is *Helicobacter pylori* resistant to antibiotics.

10. The use according to claim 9, wherein the *Helicobacter pylori* resistant to antibiotics is resistant to amoxicillin or clarithromycin.

11. The use according to claim 1, wherein the compound represented by the

formula 1, optical isomers thereof or pharmaceutically acceptable salts thereof; amoxicillin or pharmaceutically acceptable salts thereof; and clarithromycin or pharmaceutically acceptable salts thereof are prepared into an oral administration type.